ANGLE moves towards Parsortix FDA approval

Cancer diagnostics developer ANGLE (LON: AGL) is getting nearer to FDA approval for its Parsortix liquid biopsy test. Angle would be the first company to receive FDA Class II clearance for a device harvesting intact circulating tumour cells CTC), making the technology highly valuable.

The specific approval would cover breast cancer. Clearance would allow Parsortix to be used in drug trials as well as the continued monitoring of patients who have been successfully treated.

Parsortix can cap...

You are unauthorized to view this page.

Previous articleBlackRock says Biden lead stable ahead of ‘consequential election’ debate
Next articleGreggs shares fall as group takes August hit
Avatar photo
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.